Alembic Pharmaceuticals (Alembic) announced that it has received Final Approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Diltiazem ...

Refer label for a detailed indication. Diltiazem Hydrochloride Extended-Release Capsules USP, 120 mg, 180 mg, and 240 mg have an estimated market size of US$ 28.2 million for twelve months ending ...

Alembic Pharmaceuticals said that it has received final approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Diltiazem Hydrochloride ...

Alembic Pharmaceuticals Limited received final approval from the USFDA for Diltiazem Hydrochloride Extended-Release Capsules USP. The approved strengths include 120 mg, 180 mg, and 240 mg.

for Diltiazem Hydrochloride Extended-Release Capsules USP, 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg. According to company’s statement, the approved ANDA is therapeutically equivalent to the ...

Diltiazem Hydrochloride Extended-Release Capsules USP, 120 mg, 180 mg, and 240 mg. According to the company’s statement, the approved ANDA is therapeutically equivalent to the reference listed ...